Plasminogen Activator Inhibitor-1 Is Associated with Impaired Endothelial Function in Women with Systemic Lupus Erythematosus
dc.contributor.author | Somers, Emily C. | en_US |
dc.contributor.author | Marder, Wendy | en_US |
dc.contributor.author | Kaplan, Mariana J. | en_US |
dc.contributor.author | Brook, Robert D. | en_US |
dc.contributor.author | McCune, William Joseph | en_US |
dc.date.accessioned | 2010-06-01T21:28:25Z | |
dc.date.available | 2010-06-01T21:28:25Z | |
dc.date.issued | 2005-06 | en_US |
dc.identifier.citation | SOMERS, EMILY C.; MARDER, WENDY; KAPLAN, MARIANA J.; BROOK, ROBERT D.; McCUNE, W JOSEPH (2005). "Plasminogen Activator Inhibitor-1 Is Associated with Impaired Endothelial Function in Women with Systemic Lupus Erythematosus." Annals of the New York Academy of Sciences 1051(1 Autoimmune Diseases and Treatment: Organ-Specific and Systemic Disorders ): 271-280. <http://hdl.handle.net/2027.42/74531> | en_US |
dc.identifier.issn | 0077-8923 | en_US |
dc.identifier.issn | 1749-6632 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74531 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16126968&dopt=citation | en_US |
dc.description.abstract | Endothelial function, measured noninvasively by brachial artery flow-mediated dilatation (FMD), has been shown to be impaired in patients with systemic lupus erythematosus (SLE). We hypothesized that depressed FMD in SLE patients is associated with increased levels of plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis and regulator of vasoactivity. In this cross-sectional study of female SLE patients under the age of 55, putative markers of cardiovascular disease (CVD) such as PAI-1 were measured in addition to lupus-related disease activity (SLEDAI). The primary outcome, FMD, was measured using high-resolution ultrasound of the brachial artery gated to the R wave to determine endothelial-dependent vasomotion. Endothelial-independent vasomotion was measured in response to nitroglycerin (NMD). Seventy-six female SLE patients, mean age 38.3 ± 9.4 years, were included. All patients demonstrated normal NMD responses, indicating that depression of FMD was related to decreased endothelial nitric oxide production. Increased PAI-1 was related to depressed FMD by univariate regression ( P = 0.004 ). In a multivariable regression model adjusting for t-PA (tissue plasminogen activator)/PAI-1 ratio, SLEDAI, age at visit, family history of cardiovascular disease, SLE disease duration and body mass index, every 1 ng/mL increase in PAI-1 was associated with a reduction of 0.07 units FMD ( P = 0.039 ). PAI-1 was associated with impaired endothelial dysfunction, after controlling for several potential confounders. Given the high incidence of cardiovascular disease in SLE, further investigation of the role of subclinical markers of CVD is needed. | en_US |
dc.format.extent | 3219118 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2005 New York Academy of Sciences | en_US |
dc.subject.other | Systemic Lupus Erythematosus (SLE) | en_US |
dc.subject.other | Plasminogen Activator Inhibitor-1 (PAI-1) | en_US |
dc.subject.other | Endothelium | en_US |
dc.subject.other | Flow-mediated Dilatation | en_US |
dc.title | Plasminogen Activator Inhibitor-1 Is Associated with Impaired Endothelial Function in Women with Systemic Lupus Erythematosus | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Science (General) | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Division of Rheumatology, Ann Arbor, Michigan 48109, USA | en_US |
dc.contributor.affiliationum | University of Michigan, Division of Cardiology, Ann Arbor, Michigan 48109, USA | en_US |
dc.contributor.affiliationother | London School of Hygiene & Tropical Medicine, Infectious Disease Epidemiology Unit, London WC1E 7HT, UK | en_US |
dc.identifier.pmid | 16126968 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74531/1/annals.1361.068.pdf | |
dc.identifier.doi | 10.1196/annals.1361.068 | en_US |
dc.identifier.source | Annals of the New York Academy of Sciences | en_US |
dc.identifier.citedreference | Weiss, S. 1939. Diseases of the heart and the aorta which are not well recognized. Med. Clin. North Am. 5: 1323 – 1344. | en_US |
dc.identifier.citedreference | Urowitz, M.B. & D.D. Gladman. 1980. Late mortality in SLE: “the price we pay for control.” J. Rheumatol. 7: 412 – 416. | en_US |
dc.identifier.citedreference | Manzi, S., F. Selzer, K. Sutton-Tyrrell, et al. 1999. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42: 51 – 60. | en_US |
dc.identifier.citedreference | Fay, W.P., D.T. Eitzman, A.D. Shapiro, et al. 1994. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 83: 351 – 356. | en_US |
dc.identifier.citedreference | Lyon, C.J. & W.A. Hsueh. 2003. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am. J. Med. (Suppl.) 115: 62S – 68S. | en_US |
dc.identifier.citedreference | Thogersen, A.M., J.H. Jansson, K. Boman, et al. 1998. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98: 2241 – 2247. | en_US |
dc.identifier.citedreference | Gong, R., Z. Liu, Z. Chen, et al. 2002. [Genetic variations in plasminogen activator inhibitor-1 gene and beta fibrinogen gene associated with glomerular microthrombosis in lupus nephritis and the gene dosage effect]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 19: 1 – 5. | en_US |
dc.identifier.citedreference | Bick, R.L. 2000. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin. Appl. Thromb. Hemost. 6: 115 – 125. | en_US |
dc.identifier.citedreference | Bates, R.L., S.J. Payne, S.L. Drury, et al. 2003. The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus. Lupus 12: 617 – 622. | en_US |
dc.identifier.citedreference | Salazar-Paramo, M., I. Garcia de la Torre, M.J. Fritzler, et al. 1996. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis. Lupus 5: 275 – 278. | en_US |
dc.identifier.citedreference | Ruiz-Arguelles, A., E. Angles-Cano, B. Perez-Romano, et al. 1995. Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus. Am. J. Hematol. 49: 109 – 114. | en_US |
dc.identifier.citedreference | Tan, E.M., A.S. Cohen, J.F. Fries, et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25: 1271 – 1277. | en_US |
dc.identifier.citedreference | Hochberg, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40: 1725. | en_US |
dc.identifier.citedreference | Smeeth, L., S.L. Thomas, A.J. Hall, et al. 2004. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 351: 2611 – 2618. | en_US |
dc.identifier.citedreference | Bombardier, C., D.D. Gladman, M.B. Urowitz, et al. 1992. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35: 630 – 640. | en_US |
dc.identifier.citedreference | Gladman, D., E. Ginzler, C. Goldsmith, et al. 1996. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39: 363 – 369. | en_US |
dc.identifier.citedreference | 17 Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am. J. Clin. Nutr. 68: 899 – 917. | en_US |
dc.identifier.citedreference | Rajagopalan, S., R. Brook, R.H. Mehta, et al. 2002. Effect of losartan in aging-related endothelial impairment. Am. J. Cardiol. 89: 562 – 566. | en_US |
dc.identifier.citedreference | Brook, R.D., J.R. Brook, B. Urch, et al. 2002. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation 105: 1534 – 1536. | en_US |
dc.identifier.citedreference | Myers, G.L., G.R. Cooper, C.L. Winn, et al. 1989. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin. Lab. Med. 9: 105 – 135. | en_US |
dc.identifier.citedreference | Lerman, A. & A.M. Zeiher. 2005. Endothelial function: cardiac events. Circulation 111: 363 – 368. | en_US |
dc.identifier.citedreference | Fay, W.P. 2004. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc. Med. 14: 196 – 202. | en_US |
dc.identifier.citedreference | Peng, L., N. Bhatia, A.C. Parker, et al. 2002. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler. Thromb. Vasc. Biol. 22: 934 – 939. | en_US |
dc.identifier.citedreference | Farrehi, P.M., C.K. Ozaki, P. Carmeliet, et al. 1998. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97: 1002 – 1008. | en_US |
dc.identifier.citedreference | Fay, W.P., J.G. Murphy W.G. Owen. 1996. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi. Arterioscler. Thromb. Vasc. Biol. 16: 1277 – 1284. | en_US |
dc.identifier.citedreference | Zhu, Y., P.M. Farrehi & W.P. Fay. 2001. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation 103: 3105 – 10. | en_US |
dc.identifier.citedreference | Zhu, Y., P. Carmeliet & W.P. Fay. 1999. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 99: 3050 – 3055. | en_US |
dc.identifier.citedreference | Fay, W.P., A.C. Parker, L.R. Condrey, et al. 1997. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 90: 204 – 208. | en_US |
dc.identifier.citedreference | Wang, A.Y., P. Poon, F.M. Lai, et al. 2001. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int. 59: 1520 – 1528. | en_US |
dc.identifier.citedreference | Tassies, D., G. Espinosa, F.J. Munoz-Rodriguez, et al. 2000. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum. 43: 2349 – 2358. | en_US |
dc.identifier.citedreference | Sheikh, J.S., G.S. Retzinger & E.V. Hess. 1998. Association of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis. Lupus 7: 42 – 8. | en_US |
dc.identifier.citedreference | Bao, L., J. Zhou, V.M. Holers, et al. 2003. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J. Am. Soc. Nephrol. 14: 2516 – 2525. | en_US |
dc.identifier.citedreference | Hamano, K., M. Iwano, Y. Akai, et al. 2002. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am. J. Kidney Dis. 39: 695 – 705. | en_US |
dc.identifier.citedreference | Yamamoto, T., N.A. Noble, A.H. Cohen, et al. 1996. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 49: 461 – 469. | en_US |
dc.identifier.citedreference | Yamamoto, K. & D.J. Loskutoff. 1997. The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis. Am. J. Pathol. 151: 725 – 734. | en_US |
dc.identifier.citedreference | Yamamoto, K. & D.J. Loskutoff. 2000. Expression of transforming growth factor-beta and tumor necrosis factor-alpha in the plasma and tissues of mice with lupus nephritis. Lab. Invest. 80: 1561 – 1570. | en_US |
dc.identifier.citedreference | Keeton, M., C. Ahn, Y. Eguchi, et al. 1995. Expression of type 1plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int. 47: 148 – 157. | en_US |
dc.identifier.citedreference | Troyer, D.A., B. Chandrasekar, T. Thinnes, et al. 1995. Effects of energy intake on type 1 plasminogen activator inhibitor levels in glomeruli of lupus-prone B/W mice. Am. J. Pathol. 146: 111 – 120. | en_US |
dc.identifier.citedreference | Moll, S., P.A. Menoud, T. Fulpius, et al. 1995. Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. Kidney Int. 48: 1459 – 1468. | en_US |
dc.identifier.citedreference | Rajagopalan, S., E.C. Somers, R.D. Brook, et al. 2004. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103: 3677 – 3683. | en_US |
dc.identifier.citedreference | Angleton, P., W.L. Chandler & G. Schmer. 1989. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79: 101 – 106. | en_US |
dc.identifier.citedreference | Sowers, M., C. Derby, M.L. Jannausch, et al. 2003. Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. J. Clin. Endocrinol. Metab. 88: 4904 – 4910. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.